RxDoctor Payments Data

Jillian Lamarca

Physician Assistant · Buffalo, NYNPI 1891928750

Payments from drug & device makers

$7,823in general payments, 2019–2025

Across 457 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$874
  • GSK$522
  • Astellas Pharma US Inc$503
  • Pfizer$464
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,72399%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,823 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$18,552
Medicare patients
71
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$119,139
MounjaroTirzepatide71$83,811
JardianceEmpagliflozin65$67,957
EliquisApixaban40$45,965
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog32$44,386
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$24,209
Synjardy XrEmpagliflozin/Metformin Hcl21$24,143
XareltoRivaroxaban20$17,871
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$12,956
Breo ElliptaFluticasone/Vilanterol29$12,787
FarxigaDapagliflozin Propanediol11$12,276
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,424
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$10,927
EntrestoSacubitril/Valsartan15$10,181
Rosuvastatin Calcium171$3,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,664$119,13985 claims
Boehringer IngelheimJardiance, Synjardy Xr$874$92,10086 claims
Lilly USA, LLCMounjaro$1,011$83,81171 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$522$48,42090 claims
PfizerEliquis$464$45,96540 claims
AstraZenecaBreztri Aerosphere, Farxiga$212$25,23323 claims
NovartisEntresto$83$10,18115 claims
AbbVieSynthroid$320$1,69728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →